Claims for Patent: 9,200,069

Summary for Patent: 9,200,069

Title:	Low acidic species compositions and methods for producing and using the same
Abstract:	The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF.alpha. is detrimental, are also provided.
Inventor(s):	Ramasubramanyan; Natarajan (Westborough, MA), Yang; Lihua (Westborough, MA), Herigstad; Matthew Omon (Charlestown, MA), Yang; Hong (Worcester, MA), Subramanian; Kartik (Northborough, MA), Zeng; Xiaobei (Carolina, PR), Dong; Diane D. (Shrewsbury, MA), Lim; Wen Chung (Worcester, MA), Gifford; Kathreen A. (Marlborough, MA), Kaymakcalan; Zehra (Westborough, MA), Chumsae; Christopher (North Andover, MA)
Assignee:	AbbVie, Inc. (North Chicago, IL)
Application Number:	14/614,311
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,200,069
Patent Claims:	1. A method of making a pharmaceutical composition, comprising mixing (a) 25-100 mg of a low acidic species composition comprising adalimumab, wherein the low acidic species composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab have a net negative charge relative to the adalimumab main species and the acidic species comprise species selected from the group consisting of charge variants, structure variants, fragmentation variants and any combinations thereof; wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cell proteins, host cell nucleic acids, chromatographic materials and media components, and wherein said low acidic species adalimumab composition demonstrates increased cartilage penetration as compared to a non-low acidic species composition of adalimumab; and (b) a pharmaceutically acceptable carrier, thereby making a pharmaceutical composition. 2. The method of claim 1, wherein the charge variants comprise one or more of deamidation variants, glycation variants, afucosylation variants, MGO variants or citric acid variants, the structure variants comprise one or more of glycosylation variants or acetonation variants, and the fragmentation variants comprise one or more of Fab fragment variants, C-terminal truncation variants or variants missing a heavy chain variable domain. 3. The method of claim 1, wherein the percent acidic species is determined using WCX-10 HPLC, wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5) and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm, and wherein the acidic species of adalimumab are quantified based on the relative area percent of peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab. 4. The method of claim 3, wherein the adalimumab is produced in a mammalian host cell grown in cell culture. 5. The method of claim 4, wherein the mammalian host cell is selected from the group consisting of a CHO cell, an NSO cell, a COS cell, and an SP2 cell. 6. The method of claim 4, wherein the low acidic species composition comprises 8% or less, 6% or less, 3.1% or less, or 1.4% to 9% total acidic species of adalimumab. 7. The method of claim 4, wherein adalimumab is present in the pharmaceutical composition at a concentration selected from the group consisting of 50 mg/ml, 100 mg/ml, and 25-75 mg/ml. 8. The method of claim 4, further comprising filling a syringe suitable for self-injection by a patient with the pharmaceutical composition. 9. The method of claim 8, wherein the syringe is filled with 40 mg of adalimumab at a concentration of 50 mg/ml or with 40 mg of adalimumab at a concentration of 100 mg/ml. 10. The method of claim 1, wherein the pharmaceutically acceptable carrier comprises one or more excipient selected from the group consisting of a buffering agent, a surfactant and a polyol, or a combination thereof. 11. The method of claim 10, wherein the buffering agent is an amino acid. 12. The method of claim 11, wherein the amino acid is histidine. 13. The method of claim 10, wherein the surfactant is polysorbate 80. 14. The method of claim 10, wherein the polyol is mannitol. 15. A method of making a pharmaceutical composition, comprising mixing (a) 25-100 mg of a low acidic species composition comprising adalimumab, wherein the low acidic species composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5) and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm, and wherein said low acidic species adalimumab composition demonstrates increased cartilage penetration as compared to a non-low acidic species composition of adalimumab; and (b) a pharmaceutically acceptable carrier, thereby making a pharmaceutical composition. 16. The method of claim 15, wherein the acidic species of adalimumab comprise a first acidic region (AR1) and a second acidic region (AR2), and wherein the first acidic region (AR1) and the second acidic region (AR2) comprise charge variants, structure variants and fragmentation variants. 17. The method of claim 16, wherein the charge variants comprise one or more of deamidation variants, glycation variants, afucosylation variants, MGO variants or citric acid variants, the structure variants comprise one or more of glycosylation variants or acetonation variants, and the fragmentation variants comprise one or more of Fab fragment variants, C-terminal truncation variants or variants missing a heavy chain variable domain. 18. The method of claim 15, wherein the adalimumab is produced in a mammalian host cell grown in cell culture. 19. The method of claim 18, wherein the mammalian host cell is selected from the group consisting of a CHO cell, an NSO cell, a COS cell, and an SP2 cell. 20. The method of claim 18, wherein the low acidic species composition comprises 8% or less, 6% or less, 3.1% or less, or 1.4% to 9% total acidic species of adalimumab. 21. The method of claim 18, wherein adalimumab is present in the pharmaceutical composition at a concentration selected from the group consisting of 50 mg/ml, 100 mg/ml, and 25-75 mg/ml. 22. The method of claim 18, further comprising filling a syringe suitable for self-injection by a patient with the pharmaceutical composition. 23. The method of claim 22, wherein the syringe is filled with 40 mg of adalimumab at a concentration of 50 mg/ml or with 40 mg of adalimumab at a concentration of 100 mg/ml. 24. The method of claim 15, wherein the pharmaceutically acceptable carrier comprises one or more excipient selected from the group consisting of a buffering agent, a surfactant and a polyol, or a combination thereof. 25. The method of claim 24, wherein the buffering agent is an amino acid. 26. The method of claim 25, wherein the amino acid is histidine. 27. The method of claim 24, wherein the surfactant is polysorbate 80. 28. The method of claim 24, wherein the polyol is mannitol. 29. A method of making a pharmaceutical composition, comprising mixing: (a) 25-100 mg of a low acidic species adalimumab composition, wherein the low acidic species adalimumab composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab are quantified based on the relative area percent of peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5) and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm, and wherein said low acidic species adalimumab composition demonstrates increased cartilage penetration as compared to a non-low acidic species composition of adalimumab; and (b) a pharmaceutically acceptable carrier comprising a surfactant and a polyol, thereby making a pharmaceutical composition, wherein the pH of the pharmaceutical composition is between 5.0 to 6.5; and filling a syringe suitable for self-injection by a patient with the pharmaceutical composition. 30. The method of claim 29, wherein the low acidic species adalimumab composition comprises 8% or less, 6% or less, 3.1% or less, or 1.4% to 9% total acidic species of adalimumab.

Details for Patent 9,200,069

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2033-10-18